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OBJECTIVE: To evaluate the utility of the tuberculin skin
test (TST) in detecting latent and active tuberculosis (TB)
among human immunodeficiency virus (HIV) infected
patients in South India.
DESIGN: TSTs and CD4 counts were collected from 631
HIV-infected individuals without active TB and 209 anti-
retroviral and anti-tuberculosis treatment-naïve HIV-
infected patients with TB. We calculated the proportion
of TST-positive individuals, as well as the sensitivity, spec-
ificity, positive predictive value (PPV) and negative pre-
dictive value of TST in the diagnosis of TB.
RESULTS: Among subjects without active TB, 28% with
a CD4 count 100 cells/l vs. 43% of the total cohort
had a TST 5 mm (P  0.14), while the proportions
with induration 10 mm were 14% vs. 36%, respec-
tively (P  0.01). Among those with active TB, using a
5 mm cut-off, the sensitivity was 42% for those with CD4
counts 200 cells/l compared to 70% for those with
CD4 counts 200 cells/l (P  0.001). The PPV for de-
tecting active TB was 29%.
CONCLUSIONS: TST is a poor predictor of both latent
and active TB in HIV-infected individuals in TB endemic
countries. Programmes offering treatment for latent TB
should consider including all HIV-positive patients re-
gardless of TST status, or use other indicators, such as
CD4 count.
KEY WORDS: HIV; tuberculin skin test; latent tubercu-
losis infection; anergy; India
WIDESPREAD TREATMENT of latent tuberculosis
infection (LTBI) in developing countries was not rec-
ommended prior to the emergence of the human im-
munodeficiency virus (HIV) epidemic.1 However, re-
cent clinical trials suggest significant benefits from
chemoprophylaxis for HIV-infected individuals in
tuberculosis (TB) endemic countries.2,3 The World
Health Organization (WHO) currently recommends
treatment of LTBI in developing countries for HIV-
infected patients only if they have a positive tuberculin
skin test (TST).4 National guidelines for Thailand—
one of the few TB endemic countries with an estab-
lished LTBI treatment programme for HIV-infected
individuals—also recommend treatment only in TST-
positive cases.5
The TST is, however, a problematic diagnostic test
in HIV-infected individuals due to cutaneous anergy
and other causes of false-negative reactions, including
malnutrition, acute infection and improper test ad-
ministration.6–8 This high false-negative rate may pre-
vent LTBI treatment from being offered to many who
could potentially benefit from it. Moreover, opera-
tions research from developing countries has shown
that TST often complicates LTBI treatment by increas-
ing patient loss to follow-up and by raising programme
costs.9,10 Whether to base treatment of LTBI on TST
is therefore a relevant question for the development
of large-scale prevention programmes in resource-
limited settings.
We examine the utility of TST in diagnosing active
and latent TB among HIV-infected patients in South
India, and discuss the implications for programmes in
treating LTBI in developing countries.
STUDY POPULATION AND METHODS
The study population consisted of participants en-
rolled in two different randomised clinical trials per-
formed at the Tuberculosis Research Centre (TRC)
clinics in Chennai and Madurai, India, between July
2000 and June 2005. The first trial (n  631) com-
pared the efficacy of two regimens for LTBI treatment
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—a 6-month daily regimen of isoniazid (INH) and
ethambutol (EMB) vs. a 3-year course of daily INH
alone (in lieu of lifelong therapy). HIV-infected indi-
viduals without evidence of active TB were recruited
for this trial, regardless of baseline CD4 count or TST
results. Active TB was ruled out if patients were asymp-
tomatic with a normal chest X-ray and three negative
Mycobacterium tuberculosis sputum cultures.
The second trial (n  209) compared the efficacy of
treating active pulmonary TB with a 6- vs. a 9-month
course of anti-tuberculosis treatment. Antiretroviral
treatment (ART) and TB treatment naïve HIV-infected
patients newly diagnosed with pulmonary TB were
recruited. Diagnosis of active TB was based on his-
tory, physical examination and chest X-ray, and was
confirmed by an acid-fast bacilli smear or culture
positive for M. tuberculosis. For both trials, patients
fitting the above inclusion criteria were treated for
either LTBI or active TB and followed up for the dura-
tion of the trial. Patients who had data on TST results
as well as CD4 counts were included in the present
analysis.
At the time of enrolment into either trial, a TST
was performed by injecting 1 TU (tuberculin unit) of
protein purified derivative (PPD) RT23 with Tween
80 into the left forearm. The induration was measured
after 48–72 h. Blood was collected for confirmatory
HIV testing, haematological/biochemical investiga-
tions and CD4 counts (quantified by flow cytometry).
History of bacille Calmette-Guérin (BCG) vaccina-
tion was assessed based on the presence of scars.
Written informed consent was obtained from all
patients. The protocols were approved by the Institu-
tional Ethics Committee of the TRC.
To test for differences in TST positivity between pa-
tients at different CD4 count strata in the cohort with-
out active TB, one-way analysis of variance (ANOVA)
with the Bon-Ferroni multiple comparison test was
used. Pearson’s 2 test was used to examine all other re-
lationships. A receiver operating characteristics (ROC)
curve was constructed for the combined cohort to ex-
amine the sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) of
the TST for the detection of active TB at 5 mm and
10 mm cut-offs. Data are expressed as mean 	 stan-
dard deviation (SD) unless otherwise mentioned.
The study populations were drawn from clinics in
Chennai and Madurai, the two largest cities in the In-
dian state of Tamil Nadu, one of the six Indian states
with high HIV prevalence.11 Tamil Nadu still has sig-
nificant levels of socio-economic deprivation, as more
than one fifth of its population live below the poverty
line and a quarter are illiterate.12,13 Moreover, as the
government-funded clinics from which the study
population is drawn provide highly subsidised health
care, patients availing themselves of their services are
largely of a lower socio-economic status than the gen-
eral population.
RESULTS
For both cohorts, the study population largely be-
longed to the lowest socio-economic strata, with 70%
being daily wage workers in the informal sector.
Sixty-seven per cent of participants were married;
25% were illiterate and another 53% had 8 years of
formal education.
For the first clinical trial, a total of 631 individuals
(397 females and 234 males) without evidence of ac-
tive TB were eligible for this analysis. The mean age
was 30 	 7 years (range 18–60), and the mean CD4
count was 378 	 253 cells/l. In this cohort, 269
(42.6%) individuals were TST-positive based on 5 mm
and 227 (36%) based on 10 mm cut-offs (Table 1).
Using a 5 mm cut-off, 39% of females (n  155) and
48.7% of males (n  114) were TST-positive, while
34.3% of females and 38.9% of males were TST-
positive using a 10 mm cut-off (Table 1).
There was no significant difference in the rate of
TST positivity or mean induration size between older
and younger age groups. There was no significant dif-
ference in the rate of TST positivity, mean induration
size or mean CD4 cell count between patients with
and those without a history of BCG vaccination
(Table 2). Using a 5 mm cut-off, patients with CD4
counts 100 cells/l had a lower TST-positive rate of
27.6% (mean induration size 4.1 mm), as compared
to 42–48% for those with CD4 counts 100 cells/l
(mean induration size 7.9–8.5 mm) (Table 1).
For the second trial, 209 individuals (80% male)
with active pulmonary TB confirmed by positive spu-
tum culture were included in the analysis. The mean
age was 35 	 8 years (range 18–63), and the mean
CD4 count was 201 	 214 cells/l. TST-positive pa-
tients had a higher median CD4 count of 180 cells/l
compared to a median of 119 cells/l for TST-nega-
tive patients (P  0.001). In terms of age and BCG
vaccination status, there was no significant difference
in the rate of TST positivity, mean induration size or
Table 1 Tuberculin skin tests by CD4 count strata for patients 















Overall cohort 631 42.6 36.0 7.8 (9.6)
CD4 cell count, 
cells/l
0–100 58 27.6 13.8 4.1 (6.8)
101–200 100 48.0 40.0 8.4 (9.4)
201–350 187 44.9 39.6 8.5 (10.1)
351–500 126 42.9 34.1 7.9 (9.3)
500 160 41.9 38.8 7.9 (9.9)
P value 0.14 0.01 0.04
All males 234 48.7 38.9 8.4 (9.4)
All females 397 39.0 34.3 7.5 (9.7)
P value 0.05 0.27 0.27
SD  standard deviation.
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mean CD4 cell count between older and younger age
groups or between vaccinated and non-vaccinated in-
dividuals (Table 3).
The sensitivity, specificity, PPV and NPV of the
TST for detecting active TB, stratified by both 5 mm
and 10 mm cut-offs and by CD4 count strata, are pre-
sented in Table 4. The overall sensitivity varied little
based on the induration cut-off size used, with 51.2%
of the group having TST indurations 5 mm as com-
pared to 45.9% with indurations 10 mm. By con-
trast, the sensitivity varied significantly according to
the immunological status of the patient, as assessed
by CD4 count. Using a 5 mm cut-off, those with CD4
counts 200 cells/l had a significantly lower rate of
TST positivity of 42.1% (mean induration size 6.7
mm), compared to 69.6% for those with CD4 counts
200 cells/l (mean induration size 12.5 mm, P 
0.001). Using a 5 mm cut-off, the overall specificity,
PPV and NPV of the TST were respectively 57.4%,
28.5% and 78%.
DISCUSSION
While many studies from industrialised countries have
evaluated the TST in HIV infection, ours is one of the
few studies to examine this issue among HIV patients
in a developing country with high TB prevalence. In
the cohort without active TB, 39% of women and 49%
of men were TST-positive using a 5 mm cut-off, which
is the international standard for HIV-positive patients.
A previous study that screened 76 011 people from the
general population of the same Indian region found
an LTBI prevalence of 57% in women and 66% in men
using a 12 mm TST cut-off.14 Therefore, even at higher
CD4 counts, HIV-infected patients have a significantly
lower TST-positive rate compared to the general pop-
ulation. The 5 mm cut-off is not strictly comparable to
the 12 mm cut-off used for the general population; if
anything, the 5 mm cut-off would tend to overestimate
the TST-positive rate in the HIV-infected cohort.
Assuming HIV-infected patients have the same
LTBI prevalence as the general population, we calcu-
late that 154 men and 226 women should have LTBI
in the cohort without active TB. However, only 114
men and 155 women were TST-positive using a 5 mm
cut-off, making the TST only 74% and 69% sensitive
in detecting LTBI in males and females, respectively.
Using the 10 mm cut-off, the TST was only 60% sen-
sitive in both males and females.
In patients with CD4 counts 100 cells/l, the
TST fails to detect more than half of those with LTBI.
This trend probably represents cutaneous anergy, a
phenomenon well-described in studies conducted in
industrialised countries and in data from Thailand and
Table 2 TST vs. age and BCG vaccination status for individuals without active tuberculosis 


















30 336 32.1 26.1 7.3 (9.2) 420 (248)
30 295 42.4 35.6 7.6 (9.8) 329 (251)
P value — 0.76 0.80 0.72 0.001
BCG status by scar
Vaccinated 305 46.9 41.4 8.4 (9.8) 350 (210)
Not vaccinated 326 40.0 35.2 7.3 (9.5) 377 (231)
P value — 0.08 0.07 0.60 0.41
TST  tuberculin skin test; BCG  bacille Calmette-Guérin; SD  standard deviation.
Table 3 TST versus age and BCG vaccination status for individuals with active tuberculosis 


















35 107 43.0 37.6 7.1 (9.1) 212 (171)
35 102 39.2 36.2 6.6 (8.8) 193 (185)
P value — 0.60 0.52 0.42 0.68
BCG status by scar
Vaccinated 109 52.2 48.0 9.5 (10) 211 (173)
Not vaccinated 100 54.7 52.0 9.3 (9.2) 191 (178)
P value — 0.65 0.11 0.84 0.50
TST  tuberculin skin test; BCG  bacille Calmette-Guérin; SD  standard deviation.
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Ethiopia.7,15 A more unique finding from our data is
the significantly decreased rate of tuberculin reactiv-
ity even at CD4 counts 500 cells/l. A Thai study
similarly found decreased tuberculin reactivity even
at CD4 counts 400 cells/l.7 This suggests that even
selective TST screening of HIV-infected individuals
with high CD4 counts may still miss a significant pro-
portion of LTBI.
To our knowledge, this is only the second study to
evaluate TST in HIV-infected individuals with active
TB. We found a low sensitivity of TST of 51% among
HIV-infected patients with pulmonary TB, as com-
pared to 94% among 708 HIV-negative patients with
pulmonary TB (unpublished data from our clinic).
The PPV of the TST for detecting active TB is low in
TB-endemic areas (29% in this study). While the NPV
was high at higher CD4 counts, it was poor in immuno-
suppressed individuals. Many doctors in India and
other countries still rely on TST as part of their diag-
nostic workup for active TB. These data show that
TST should not be used in this manner, especially in
HIV-infected individuals.
Cobelens et al. suggest that there are limited bene-
fits in using a 5 mm induration cut-off to define a pos-
itive TST in HIV-positive patients as compared to the
10 mm cut-off used in non-HIV-infected patients.16
Our data support this finding for HIV-infected pa-
tients at most CD4 count strata, as the difference be-
tween positivity rates using a 5 mm vs. 10 mm cut-off
for detection of either latent or active TB was mini-
mal. However, at CD4 counts 100 cells/l, the 5 mm
cut-off detected twice as many cases of LTBI (28% vs.
14%) as the 10 mm cut-off. The more sensitive 5 mm
cut-off may therefore still be beneficial in this subset
of severely immunosuppressed patients.
Current WHO guidelines recommend LTBI treat-
ment in HIV-infected patients only if they have a pos-
itive TST.4 However, debate remains as to whether
treatment of LTBI benefits TST-negative patients.
While some studies show statistically significant ben-
efits from treating LTBI in TST-negative individu-
als,17,18 two major meta-analyses support the WHO
position by showing milder benefits that did not reach
statistical significance.19,20 In contrast, our data sug-
gest that a large proportion of HIV-infected individuals
in this TB-endemic area are likely to have LTBI despite
being TST-negative, suggesting many TST-negative
patients would benefit from LTBI treatment. This find-
ing is supported by similar data from Thailand7 and a
previous study of HIV-infected patients in South India,
which found that TST-positive and -negative patients
developed active TB at similar incidence rates of re-
spectively 7.1 and 6.7 cases per 100 person-years.21
While we can only speculate on the reasons for this
discrepancy between our own findings and those of
prior meta-analyses, this incongruity may partly be
due to the inclusion in these meta-analyses of data
from diverse geographical regions (i.e., sites in the
US vs. sites in Africa), which may have very different
prevalences of LTBI in the general population. In low
TB prevalence settings such as the US, most TST-neg-
ative HIV-infected individuals are unlikely to have
been exposed to TB (i.e., the TST has a higher NPV
due to low TB prevalence). Treatment of TST-nega-
tive patients in this context is therefore unlikely to
produce a significant decrease in the rate of reactiva-
tion TB.
By contrast, in South India, where nearly two thirds
of the population is latently infected with TB, the TST
has a low NPV and ‘misses’ a larger proportion of
LTBI. Treatment of TST-negative HIV-infected indi-
viduals is therefore likely to have a more favourable
risk-benefit ratio. More benefit in TST-negative indi-
viduals may be expected in places with even higher
TB prevalence, such as the South African gold mines,
which have a remarkably high TB rate due to perva-
sive silica dust exposure and HIV infection.3 There-
fore, rather than endorsing a one-size-fits-all answer
to the question of whether TST screening should be
used in programmes that treat LTBI in HIV-infected
populations, we believe that this decision should be
based partly on the local LTBI prevalence in the gen-
eral population, as well as on local data assessing the
efficacy of treating TST-negative individuals.
Finally, operations research also provides mixed
evidence as to whether the TST should be used in
LTBI treatment programmes. While one study from
Uganda suggests that use of the TST is cost-effective,22
other studies from Thailand and Uganda found that
TST screening is associated with higher patient drop-
out rates before treatment initiation.9,10 The Ugandan
study found that 19% of patients who had a TST placed
Table 4 Accuracy of the TST for detection of active tuberculosis in South India (n  840)

















(all CD4 cell counts)
(n  840)
Sensitivity 42.1 69.6 51.2 36.4 65.2 45.9
Specificity 60.0 56.5 57.4 69.0 62.4 64.0
PPV 48.8 18.8 28.5 51.5 20.1 29.7
NPV 53.4 92.8 78.0 54.6 92.5 78.1
TST  tuberculin skin test; PPV  positive predictive value; NPV  negative predictive value.
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did not return at the appropriate time for follow-up
test reading.10 Another Thai study found that 86% of
physicians providing LTBI treatment did not rou-
tinely perform TST despite its being part of the na-
tional guidelines.5
Other factors that we examined, such as age and
BCG vaccination status, did not have a statistically
significant influence on the operational characteristics
of TST. The lack of influence of BCG vaccination is
supported by a recent meta-analysis finding only a
1% false-positive rate attributable to BCG.23 As the
majority of our patients belonged to the lowest socio-
economic group, we were not able to perform a mean-
ingful analysis of the impact of socio-economic factors
on the TST.
In summary, our data suggest that TST underesti-
mates the extent of LTBI in HIV-infected individuals
in South India, with a sensitivity of only 69–74% even
among patients with less advanced HIV. Guidelines in
developing countries basing LTBI treatment in HIV-
positive individuals on a positive TST may prevent
therapy from being offered to many who could benefit
from it, apart from increasing costs and patient drop-
out rates. Programmes offering LTBI treatment should
partly base the decision to implement TST screening
on the local prevalence of LTBI in the general popula-
tion. Programmes in high TB prevalence settings should
consider including all HIV-infected patients, regard-
less of TST status, or use other treatment indicators,
such as CD4 count or total lymphocyte count.24,25
Current WHO guidelines recommend initiation of ART
in asymptomatic HIV-infected individuals only at CD4
counts 200 cells/l.26 As a significant proportion of
HIV-infected individuals in TB endemic settings expe-
rience an episode of active TB even at CD4 counts 200
cells/l,24 liberalisation of current CD4 count guide-
lines for initiation of ART may be an additional ap-
proach for preventing TB among individuals living
with HIV in developing countries.
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R É S U M É
OBJECTIF : Evaluer l’utilité du test cutané tuberculinique
(TST) pour la détection de la tuberculose (TB) latente et
active chez les patients infectés par le virus de l’immuno-
déficience humaine (VIH) en Inde du Sud.
SCHÉMA : On a examiné le TST et le décompte de CD4
chez 631 individus infectés par le VIH et sans TB active
ainsi que chez 209 patients infectés par le VIH et atteints
de TB mais sans traitement antirétroviral ou antituber-
culeux. Nous avons calculé le pourcentage d’individus à
TST positif ainsi que la sensibilité, la spécificité, la valeur
prédictive positive (VPP) et la valeur prédictive négative
du TST pour le diagnostic de la TB.
RÉSULTATS : Parmi les sujets sans TB active, 28% des
patients dont le décompte de CD4 était 100 cellules/l
versus 43% de la cohorte totale avaient un TST 5 mm
(P  0,14), alors que les proportions avec une indura-
tion 10 mm ont été respectivement de 14% vs. 36%
(P  0,01). Parmi les sujets atteints de TB active, l’utili-
sation d’une limite de 5 mm a donné une sensibilité de
42% pour ceux dont les décomptes de CD4 étaient 200
cellules/l, par comparaison avec 70% pour ceux dont
les décomptes étaient 200 cellules/l (P  0,001). La
VPP pour la détection d’une TB active a été de 29%.
CONCLUSIONS : Chez les individus infectés par le VIH et
vivant dans des pays où la TB est endémique, le TST est
un facteur prédictif médiocre tant de la TB latente que
de la TB active. Les programmes offrant un traitement
pour la TB latente devraient considérer d’y inclure tous
les patients séropositifs pour le VIH, quel que soit leur
statut de TST, ou encore utiliser d’autres indicateurs
comme le décompte des CD4.
R E S U M E N
OBJETIVO : Evaluar la utilidad de la prueba cutánea de
la tuberculina (TST) en la detección de tuberculosis (TB)
latente y activa en pacientes infectados por el virus de la
inmunodeficiencia humana (VIH) en el sur de la India.
MÉTODO : Se recogieron datos de los resultados de la
TST y del recuento de linfocitos CD4 de 631 pacientes
con infección por el VIH, sin TB activa y 209 infectados
por el VIH, con TB y sin antecedentes de tratamiento
antirretrovírico ni antituberculoso. Se calculó el porcen-
taje de reacción positiva a la TST y la sensibilidad, espe-
cificidad, valor de predicción positiva (VPP) y valor de
predicción negativa de la TST en el diagnóstico de TB.
RESULTADOS : En la cohorte de pacientes sin TB activa,
se observó una reacción cutánea a la TST de 5 mm
en 28% de los pacientes con recuentos de CD4 100
células/l y en 43% de los pacientes con recuentos supe-
riores (P  0,14) ; la induración de 10 mm estuvo pre-
sente en 14% de aquellos con 100 células CD4/l y en
36% de quienes tuvieron recuentos más altos (P 
0,01). En la cohorte de pacientes con TB activa el um-
bral de 5 mm tuvo una sensibilidad de 42% en pacientes
con recuento de CD4 200 células/l y de 70% en
aquellos con recuentos 200 células/l (P  0,001). El
VPP de TB activa fue 29%.
CONCLUSIÓN : La TST es un débil indicador de TB la-
tente y activa en individuos infectados por el VIH en
países endémicos. Los programas que ofrecen trata-
miento de la TB latente deberían contemplar la inclusión
de todos los pacientes con serología positiva para el
VIH, sin tener en cuenta el resultado de la TST ni otros
indicadores como el recuento de CD4.
